ESR1 and breast carcinoma: We also investigated the preventive effect of Raloxifene, new SERMs (Selective Estrogen Receptor Modulators) with mixed agonist/antagonist properties, on estrogen receptor, and identified the potential reduction in the risk of breast cancer (Barrett-connor 2001; Kim et al. 2002).